In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Firmenich takes the reins

This article was originally published in The Rose Sheet

Executive Summary

Patrick Firmenich to take the helm of privately-owned flavors and fragrance supplier effective July 1, representing the fourth generation of the Firmenich family to control the company. Exec will succeed his uncle, Pierre-Yves Firmenich, who has served as CEO since 1989. Patrick Firmenich began working for the company in 1990. In 1993, he was appointed VP-fine fragrances and in 1997 became responsible for fine fragrance worldwide and president of the Firmenich affiliate in Paris, the Geneva company says. In 2001, he joined the worldwide headquarters as corporate VP-special projects...

You may also be interested in...


Michel Bongi to corporate VP-worldwide perfumery division from VP-corporate development for perfumery, fragrance and flavors supplier announces. Bongi, who will be based at Firmenich's Geneva headquarters, is succeeding Jean-Pierre Linder, who retired effective June 30. Change coincides with Patrick Firmenich's appointment to CEO. Exec will succeed his uncle Pierre-Yves Firmenich effective July 1 (1"The Rose Sheet" June 3, 2002, In Brief)...

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts